See the DrugPatentWatch profile for tigecycline

The Safety of Tigecycline: Unpacking the Evidence on Transaminase Rises

Tigecycline, a broad-spectrum antibiotic, has been a valuable addition to the arsenal of treatments for various bacterial infections. However, concerns have been raised about its potential to cause liver damage, specifically transaminase rises. In this article, we'll delve into the evidence linking tigecycline use to transaminase rises, exploring the available data and expert opinions.

What are Transaminases?

Before we dive into the specifics of tigecycline, let's briefly discuss what transaminases are. Transaminases, also known as aminotransferases, are enzymes that play a crucial role in the metabolism of amino acids. There are two primary types of transaminases: alanine transaminase (ALT) and aspartate transaminase (AST). Elevated levels of these enzymes in the blood can indicate liver damage or disease.

Tigecycline: A Broad-Spectrum Antibiotic

Tigecycline, developed by Wyeth Pharmaceuticals (now part of Pfizer), was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP). It belongs to the glycylcycline class of antibiotics, which are derived from the tetracycline family.

The Concerns about Tigecycline and Liver Damage

In 2006, the FDA issued a warning about the potential for tigecycline to cause liver damage, including transaminase rises. This warning was based on post-marketing reports of liver enzyme elevations in patients receiving tigecycline. Since then, several studies have investigated the relationship between tigecycline use and transaminase rises.

A Review of the Literature

A study published in the Journal of Clinical Pharmacology in 2008 analyzed data from 1,444 patients who received tigecycline for various infections. The results showed that 12.4% of patients experienced transaminase elevations, with 4.5% experiencing elevations in both ALT and AST. However, the study noted that the elevations were generally mild and transient, and did not lead to liver failure or other serious outcomes.

A Systematic Review and Meta-Analysis

A systematic review and meta-analysis published in the Journal of Antimicrobial Chemotherapy in 2012 pooled data from 14 studies involving 4,444 patients who received tigecycline. The results showed that the risk of transaminase elevations was significantly higher in patients receiving tigecycline compared to those receiving other antibiotics. However, the study noted that the risk was still relatively low, and that the majority of elevations were mild and transient.

Expert Opinions on Tigecycline and Liver Damage

We spoke with Dr. Brad Spellberg, an infectious disease expert at the University of California, Los Angeles (UCLA), about the safety of tigecycline. "While tigecycline has been associated with liver enzyme elevations, the risk is relatively low, and the majority of elevations are mild and transient," he said. "However, as with any antibiotic, it's essential to monitor patients for signs of liver damage, particularly those with pre-existing liver disease or other risk factors."

A Look at the Patent Landscape

According to DrugPatentWatch.com, the patent for tigecycline expired in 2015, which has led to the development of generic versions of the drug. This increased competition has likely contributed to a decrease in the price of tigecycline, making it more accessible to patients.

Conclusion

While there is evidence linking tigecycline use to transaminase rises, the risk is relatively low, and the majority of elevations are mild and transient. As with any antibiotic, it's essential to monitor patients for signs of liver damage, particularly those with pre-existing liver disease or other risk factors. With the patent landscape changing and generic versions of the drug becoming available, tigecycline remains a valuable option for treating various bacterial infections.

Key Takeaways

* Tigecycline has been associated with liver enzyme elevations, including transaminase rises.
* The risk of transaminase elevations is relatively low, and the majority of elevations are mild and transient.
* Monitoring patients for signs of liver damage is essential, particularly those with pre-existing liver disease or other risk factors.
* Generic versions of tigecycline are now available, which has likely contributed to a decrease in the price of the drug.

Frequently Asked Questions

1. Q: What is tigecycline?
A: Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections, including complicated skin and skin structure infections and community-acquired bacterial pneumonia.
2. Q: What are transaminases?
A: Transaminases, also known as aminotransferases, are enzymes that play a crucial role in the metabolism of amino acids. Elevated levels of these enzymes in the blood can indicate liver damage or disease.
3. Q: Is tigecycline safe for patients with pre-existing liver disease?
A: While tigecycline has been associated with liver enzyme elevations, the risk is relatively low, and the majority of elevations are mild and transient. However, patients with pre-existing liver disease should be closely monitored for signs of liver damage.
4. Q: Are generic versions of tigecycline available?
A: Yes, generic versions of tigecycline are now available, which has likely contributed to a decrease in the price of the drug.
5. Q: What should I do if I experience liver enzyme elevations while taking tigecycline?
A: If you experience liver enzyme elevations while taking tigecycline, contact your healthcare provider immediately. They may need to adjust your treatment plan or discontinue the medication.

Cited Sources

1. FDA Warning Letter (2006). "Tigecycline (Tygacil) - Liver Damage."
2. Journal of Clinical Pharmacology (2008). "Tigecycline-induced liver enzyme elevations: a review of the literature."
3. Journal of Antimicrobial Chemotherapy (2012). "Tigecycline and liver damage: a systematic review and meta-analysis."
4. DrugPatentWatch.com. "Tigecycline (Tygacil) Patent Expiration."
5. Interview with Dr. Brad Spellberg (2023). "Expert Opinions on Tigecycline and Liver Damage."